Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog



854 Features
Clinical data further demonstrates the efficacy of Pfizer's pregabalin (Lyrica) in the treatment of diabetic neuropathic pain

25 Aug 04

DailyUpdates 25th August, 2004: Despite legal appeals by Pfizer, Ivax's generic equivalent of the blockbuster gabapentin (Neurontin) went on sale earlier this month increasing the need for Pfizer to push the follow-on, pregabalin onto the US market. Pregabalin was approved by European authorities in July of this year for the treatment of peripheral neuropathic pain and as an adjunctive therapy for partial seizures in patients with epilepsy. Most recently a US study has been published data furthe

Low level carbon monoxide exposure as a therapeutic approach to improving transplant outcome

24 Aug 04

DailyUpdates 24th August, 2004: Heme oxygenase-1 (HO-1), one of the enzymes responsible for the production of carbon monoxide, is induced under conditions of ischemic stress. Clinical data has previously demonstrated that increased expression of HO-1 may limit post-transplant ischemia reperfusion injury, a major cause of reduced graft survival. Now researchers have reported that maintaining transplant recipients in an atmosphere of elevated carbon monoxide promotes extended graft survival

Clinical data supports the development of insulin as a future treatment for memory and mood disorders?

23 Aug 04

DailyUpdates 23rd August, 2004: The use of insulin forms the cornerstone of diabetes treatment. A body of data also suggests however that this hormone directly modulates both memory and mood suggesting that endogenous insulin may be of benefit to many of the 180 million people around the world with memory disorders, and especially those with co-morbid mood disturbances such as schizophrenic or depressed individuals. A recent study has shown that intra-nasal administration of insulin improves m


23 Aug 04

Eventually, methods developed by research laboratories need to be transferable to face the rigours of external validation or the production line. Many researchers, however, are unaware that this procedure must be adequately documented, a crucial issue when it comes to regulation and outsourcing.
Rachel Holdsworth/Geoff Pulham

It's not just drug discovery that's an expensive business

23 Aug 04

Pharmaceutical practices from manufacturing to marketing are coming under increasing scrutiny from watchdogs, regulators and shareholders. As huge fines and record settlements erode profits, Datamonitor's Andrew Jones argues that pharma companies must focus on tightening compliance...

The future is outsourced

23 Aug 04

As the pharmaceutical market becomes more competitive and the R&D process more complex, companies have began to use outsourcing on a longer-term basis than in the past. For observers in other R&D-based industries the pharmaceutical industry is a somewhat conservative user of outsourcing, and yet the pharmaceutical industry’s R&D investment as a proportion of sales is much higher than these other technology sectors.
Dr Faiz Kermani

Researchers report on the role of estrogen in airway function: Can menopause accelerate the progression of COPD?

19 Aug 04

DailyUpdates 18th August, 2004: Recent data suggest that women may be more susceptible to the chronic airway disorders emphysema and bronchitis, together known as chronic obstructive pulmonary disease (COPD). The reasons for this are unclear however data published this month demonstrate a key role of the estrogen receptor in maintaining alveolar surface area and airway elasticity. This suggests that menopause may contribute to the acceleration of COPD and prompts investigation into the develop

Can you Sell Yourself?

18 Aug 04

After my many years of conducting interviews and recruiting for both junior and senior employees, I have come to the conclusion that if there is one single thing that a person can do to secure a second interview or a desired position it is believe in themselves.
Susan Mason

Antibody-drug conjugates offer hope for the treatment of hormone resistant prostate cancer

17 Aug 04

DailyUpdates 17th August, 2004: Researchers from Protein Design Laboratories report that an antibody-drug conjugate that links the chemotherapeutic agent Auristatin to a prostate cancer specific antibody, anti-TMEFF2 mAb, via a cathepsin B-sensitive linker prevents tumor growth in a murine model of prostate cancer.

Proteolytic beta amyloid light chain antibody fragments offer promise as future treatments of Alzheimer’s disease.

17 Aug 04

DailyUpdates 18th August, 2004: Researchers from at Arizona State University have demonstrated that beta amyloid light chain proteolytic antibody fragments can cleave beta-amyloid, altering the aggregation and neutralizing the cytotoxic effects of this peptide.

New rhinitis therapy should help patients to breathe easy

13 Aug 04

Rigel's new intranasal inhibitor R112 could offer a useful alternative therapy for patients suffering from allergic rhinitis, as Datamonitor's Shaun Falkingbridge explains. Bolstered by supportive recent trial results, Rigel can now go on to seek partner firms to realize full commercialization of the drug...

US online pharmacies can attract consumers from cross-border discounters

12 Aug 04

The trade in discounted prescription drugs between Canada and the US has elicited considerable controversy on both sides of the border. Yet recent figures show that sales of drugs via Canadian pharmacies have not been as great as some had predicted. However, as Datamonitor's David Deon explains, pharmaceutical companies could go further by driving the expansion of online prescribing in the US...

Lipoxin A4 (LXA4) mimics shown reduce inflammation by inhibiting the p38-MAPK pathway-further proof of concept for LXA4 analogues in preclinical development

11 Aug 04

The p38-MAPK pathway has long been targeted by the pharmaceutical industry in an attempt to identify new anti-inflammatory agents. The development of p38-MAPK inhibitors has however been impeded by adverse effects. Boston University researchers have now demonstrated that the lipoxin A4 (LXA4) mimic, ATLa inhibits the p38-MAPK cascade explaining in part its anti-inflammatory efficacy and offering a new approach to this promising pharmaceutical target. Although ATLa has a poor pharmacokinetic p

France feels out the future of biotech

10 Aug 04

After a period of exceptional performance due to a steady flow of investment in the sector, the biotechnology industry in France was hard hit by the global economic depression of 2002. The government must support the French Biotechnology sector to allow it to assert its position at an international level and to enable consolidation of new start-up companies.
Yohan Vezinhet

Big bucks battling super bugs?

03 Aug 04

Bacterial skin diseases like gangrene can now expect an onslaught of new specialist medications. However, skin infections make up a relatively small proportion of the $20.4 billion annual global antibacterial market, which, says Datamonitor's Amber Gibson, raises questions about why such conditions are the current focus of so much antibacterial product development...

Generics companies step into the unknown…

29 Jul 04

Although generics have an important role to play in healthcare there remains a high demand for innovative medicines. Consequently, a number of generics companies have become interested in extending their R&D programmes to make their products appear more than simple copies of their branded competitors.
Dr Faiz Kermani

Pharmaceutical companies set to make a significant profit from anti-obesity drugs

26 Jul 04

By 2012, the anti-obesity drugs market will be worth an estimated $2.5 billion globally, compared to $526 million today. However, new drugs will not be the answer to the growing obesity problem. Datamonitor's Jasjeet Mohain argues that increasing education and awareness of the importance of good diet and exercise will remain crucial to combating obesity...

Roche's Fuzeon offers the 20% of patients that receive it

19 Jul 04

New clinical research presented at the 15th International AIDS Conference (IAC) shows that Fuzeon is proving to be remarkably effective in the first long-term trial of its benefits.

Advances in the development of corticotropin-releasing-hormone (CRH) receptor agonists as candidate analgesics

13 Jul 04

Acute pain resulting from conditions such as headache, muscle spasms, dental problems or following surgery, affects 90 million Americans every year. A recent study has demonstrated the analgesic activity of corticotropin-releasing-hormone (CRH) and has shown that this activity is probably due to activity within the central nervous system.

The emerging role of the IL-4/IL-3 cytokine receptor IL-4Ralpha in asthma

09 Jul 04

Analysts have recently predicted that the market for airway inflammatory diseases will increase by 35% to over $18 billion by 2011. A recent target evaluation report produced for the drug development sector concluded that the TH2-derived cytokines IL-4, and more so IL-13 represent promising targets. Both cytokines activate IL-4Ralpha to produce multiple functional changes observed in asthma patients. A recent report published in the Journal of Immunology elucidates the divergent mechanisms th

Strong potential for cross risk-factor single pill therapies

09 Jul 04

Recently published data from the GENOA study has demonstrated that dyslipidemia is highly prevalent in hypertensive adults and that this condition is insufficiently treated in more than half of the cases. As Datamonitor's Laurent Chanroux explains, the results lend further support to cross risk-factor, single pill combination therapies such as Pfizer's Caduet...


05 Jul 04

Metabolic syndrome, a cluster of common metabolic disorders including obesity, pre-diabetes, abnormal lipid levels and high blood pressure, is now approaching epidemic proportions worldwide.

Driving Drug Discovery through External R&D Resources

30 Jun 04

Post-Conference Workshop: Structuring the Deal-- Contract Development and Negotiations for Improved Results
Kelly Cavin

Emerging Drug Discovery Targets; June 28th

29 Jun 04

This edition of "Emerging Drug Discovery Targets" features new approaches to improving intestinal uptake of poorly absorbed therapeutics; a dual 5-LO inhibitor/H1 receptor antagonist for the treatment of asthma; Sitaxentan as an effective treatment of pulmonary arterial hypertension; Kv1.3 potassium channel blockade as an approach to insulin resistance; Drug delivery technology predicted to allow safer and more effective use of steroids in the treatment of rheumatoid arthritis; VEGF receptor tyr

Novartis’/Schering’s VEGF receptor tyrosine kinase inhibitor, PTK787/ZK222584 as a candidate treatment of rheumatoid arthritis.

25 Jun 04

Rheumatoid arthritis is one of the more common autoimmune diseases. LeadDiscovery’s recent state of the art evaluation of rheumatoid arthritis therapeutics evaluates advances in our understanding of the etiology of the disease. One field of research extensively analyzed in this report is angiogenesis. Inhibitors of receptor tyrosine kinase with specific activity against the VEGFRs have been developed in an attempt to prevent angiogenesis. One such molecule is PTK787/ZK222584, synthesized and dev

Drug delivery technology predicted to allow safer and more effective use of steroids in the treatment of rheumatoid arthritis

23 Jun 04

An estimated 5 million individuals suffer from rheumatoid arthritis. Corticosteroids are the most dramatically effective short-term anti-inflammatory drugs; however, clinical benefit for rheumatoid arthritis often diminishes with time. Because of their long-term systemic side effects, corticosteroids are usually given only after a careful and prolonged trial of less hazardous drugs. Liposomes are artificial vesicles efficiently phagocytosed by macrophages and recent advances such as the developm

Kv1.3 potassium channel blockade as an approach to insulin resistance

22 Jun 04

The R&D activity surrounding novel oral treatments of diabetes is considerable and one particular target that has recently received attention is the Kv1.3 potassium channel. Blocking this channel has been thought to be of value in the treatment of multiple sclerosis and more recently for preventing weight gain. Now researchers from Yale have demonstrated that Kv1.3 channel blockers may also increase insulin sensitivity in genetically obese and diabetic mice

Sitaxentan as an effective treatment of pulmonary arterial hypertension

21 Jun 04

Pulmonary arterial hypertension (PAH) represents an unmet market. Initial breakthroughs in treatment focussed on the rare form of this condition, idiopathic pulmonary arterial hypertension. Recently however a key advance in the treatment of PAH was made with the launch of Actelion's twice-daily Tracleer (bosentan) as the first orally active treatment of both idiopathic and secondary PAH. Tracleer is the first generation of a class of drugs known as endothelin receptor antagonists and blocks two

The development of a dual 5-LO inhibitor/H1 receptor antagonist for the treatment of asthma

20 Jun 04

Numerous inflammatory mediators have been implicated in the etiology of asthma. Blocking specific inflammatory mediators has frequently yielded unimpressive clinical results and instead the simultaneous targeting or more than one mediator may be of greater use. In the current edition of LeadDiscovery's TherapeuticAdvances work by researchers at UCB who have developed a dual 5-LO inhibitor/H1 receptor antagonist is highlighted

PABORD - dedicated to Outsourcing in Research and Development

17 Jun 04

PABORD is the first exhibition and conference dedicated to Outsourcing in Research and Development for the Pharmaceutical and Biotechnology industries.
Simon Berger

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.